The estimated Net Worth of Massimo Calafiore is at least $880 Thousand dollars as of 1 March 2022. Mr. Calafiore owns over 8,699 units of Nuvasive Inc stock worth over $409,226 and over the last 4 years he sold NUVA stock worth over $470,442. In addition, he makes $0 as Executive Vice President - Global Business Units at Nuvasive Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Calafiore NUVA stock SEC Form 4 insiders trading
Massimo has made over 5 trades of the Nuvasive Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 8,699 units of NUVA stock worth $345,785 on 1 March 2022.
The largest trade he's ever made was exercising 8,699 units of Nuvasive Inc stock on 1 March 2022 worth over $345,785. On average, Massimo trades about 2,468 units every 36 days since 2021. As of 1 March 2022 he still owns at least 10,295 units of Nuvasive Inc stock.
You can see the complete history of Mr. Calafiore stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Massimo Calafiore biography
Massimo Calafiore serves as Executive Vice President - Global Business Units of the Company. Mr. Calafiore joined NuVasive in 2017, and most recently served as senior vice president of the Spine Business Unit. Prior to NuVasive, he spent the previous 16 years supporting and leading the U.S. business for Waldemar Link, a leader in the orthopedics and medical device industry.
What's Massimo Calafiore's mailing address?
Massimo's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Insiders trading at Nuvasive Inc
Over the last 21 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair, and Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.
What does Nuvasive Inc do?
nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through
What does Nuvasive Inc's logo look like?
Complete history of Mr. Calafiore stock trades at Nuvasive Inc and Orthofix Medical Inc
Nuvasive Inc executives and stock owners
Nuvasive Inc executives and other stock owners filed with the SEC include:
-
J. Christopher Barry,
Chief Executive Officer, Director -
J. Christopher Barry,
CEO & Director -
Nathaniel Sisitsky,
Senior Vice President, General Counsel, Corporate Secretary -
Matthew K. Harbaugh,
Exec. VP & CFO -
Gregory Lucier,
Chairman of the Board -
Nathaniel B. Sisitsky Esq.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Lucas Vitale,
Sr. VP & Chief HR Officer -
Donald Rosenberg,
Independent Director -
Daniel Wolterman,
Independent Director -
Vickie Capps,
Independent Director -
Leslie Norwalk,
Independent Director -
R. Scott Huennekens,
Independent Director -
Robert Friel,
Independent Director -
John DeFord,
Independent Director -
Suzanne Hatcher,
Vice President, Internal & External Affairs -
Dale Wolf,
Senior Vice President - Global Operations -
Massimo Calafiore,
Executive Vice President - Global Business Units -
Brent Boucher,
Executive Vice President - Global Commercial -
Lucas Vitale,
Chief Human Resource Officer -
Matthew Harbaugh,
Executive Vice President, Chief Financial Officer -
Marc Rosenbaum,
VP, Corp. Controller & Chief Accounting Officer -
Michael Farrington,
VP of Corp. Marketing, Brand & Communication -
Juliet C. Cunningham,
VP of Investor Relations -
Ryan Donahoe,
Chief Technology Officer -
Dale A. Wolf,
Sr. VP of Global Operations -
Lisa Pecora,
VP & Head of Global Commercial Fin. -
Frank Middeke,
Managing Director of DACH -
Sean Freeman,
Sr. VP of Strategy & Corp. Devel. -
Johnson Lai,
Chief Information Officer -
Jereme M Sylvain,
Chief Accounting Officer -
Jack R Blair,
Director -
Peter Michael Leddy,
Director -
Edmund J Roschak,
CEO, NuVasive Spec. Orthopedic -
Dan Wolterman,
Director -
Michael D Ohalleran,
Director -
Lesley H Howe,
Director -
Peter C Farrell,
Director -
Joan Stafslien,
EVP and General Counsel -
Quentin S. Blackford,
CFO and CAO -
Cox Carol,
EVP Strategy, Corp Dev -
Tyler Lipschultz,
EVP, Biologics -
Andrew C. Morton,
SVP, CHRO -
Matthew Link,
President -
Rajesh Asarpota,
CFO -
Paul Mc Clintock,
President, U.S. Commercial -
Stephen Rozow,
EVP, Global Process -
Jeffrey P Rydin,
Senior V.P., U.S. Sales -
Jason Hannon,
VP, Legal Affairs & Secretary -
Patrick Miles,
Senior VP, Marketing -
Kevin C Oboyle,
CFO and Executive VP -
James C Blair,
Director -
James J Skinner,
VP,Strategic Sales Development -
Jonathan Spangler,
VP & Chief Patent Counsel -
G Bryan Cornwall,
VP, Research & Development -
Hansen A Yuan,
Director -
Arda Minocherhomjee,
Director -
Blair Capital Management Vi...,
-
Perkins Caufield & Byers Vi...,
10% owner -
Joseph Lacob,
Director -
G Rogan Fry,
Sr. V. P., Corp. Development -
Viii Associates Lp Kpcb,
10% owner -
Life Sciences Zaibatsu Fund...,
10% owner -
Iv Associates Lp Dp,
10% owner -
Jesse I Treu,
10% owner -
Kathleen K Schoemaker,
10% owner -
Brian H Dovey,
10% owner -
Vii Associates Lp Kpcb,
10% owner -
De Depot Et Placement Du Qu...,
10% owner -
Management Partners Iv Lpen...,
-
Partners Iv Lp Domain,
10% owner -
Viii Founders Fund L P Kpcb,
10% owner -
Russell Powers,
Exec. VP Sales Int'l Ops -
Eileen M More,
Director -
Keith Valentine,
President -
Alexis V Lukianov,
CEO and Chairman -
Michael E Paolucci,
Exec. V.P., Global HR -
Craig E Hunsaker,
SVP, Global Human Resources -
Richard Iii Treharne,
Director -
Michael Lambert,
CFO and Executive VP -
Robert J Hunt,
Director -
Siddhartha Kadia,
Director -
Amy Belt Raimundo,
Director -
Michael Farrington,
SVP, People and Culture -
Marc W. Rosenbaum,
Chief Accounting Officer